Good news, bad news for Impax

The FDA has given tentative approval for an ANDA for a generic version of Eli Lilly's Cymbalta, a drug that treats depression and general anxiety. At the heart of the new drug is Impax Laboratories' drug delivery technology, a Hayward, CA-based company that specializes in controlled release for generics. TradingMarkets.com reports that Cymbalta saw $3 billion in U.S. sales this past year. That was the good news for Impax. The bad news is that it is being sued by a unit of Johnson & Johnson over alleged patent infringement in its attempt to market a generic version of the ADHD drug Concerta. Generic Cymbalta report |  Generic Concerta news

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.